Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #702

    Janssen Announces New Data Supporting Safety and Efficacy of RYBREVANT® and Lazertinib Combination for Patients with Non-Small Cell Lung Cancer and EGFR Mutations https://www.prnewswire.com/news-releases/janssen-announces-new-data-supporting-safety-and-efficacy-of-rybrevant-and-lazertinib-combination-for-patients-with-non-small-cell-lung-cancer-and-egfr-mutations-301593280.html

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #703

      Hvad hjælper det JnJ sender en PR kl. 15.29, når E L har breaket 14:53.....

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #704

        haha really? maybe they want us to proof-read it first 😉

        1 Reply Last reply
        0
        • D Offline
          D Offline
          deleted-user
          wrote on sidst redigeret af
          #705

          Haha. I would like to subscribe E L when its possible

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #706

            joking aside, it is important data on the road to approval outside of
            the EGFR Exon 20 patients

            1 Reply Last reply
            0
            • D Offline
              D Offline
              deleted-user
              wrote on sidst redigeret af
              #707

              Do you calculate NAV for Amivantamab these days?

              1 Reply Last reply
              0
              • P Offline
                P Offline
                ProinvestorNEWS
                wrote on sidst redigeret af
                #708

                USA/åbning: Walmart falder til bunds i rødt marked efter nedjustering
                https://www.proinvestor.com/investornyt/855566/usa-abning-walmart-falder-til-bunds-i-rodt-marked-efter-nedjustering

                1 Reply Last reply
                0
                • B Offline
                  B Offline
                  bikube
                  wrote on sidst redigeret af
                  #709

                  Og $ stiger nu 7,35.

                  1 Reply Last reply
                  0
                  • D Offline
                    D Offline
                    deleted-user
                    wrote on sidst redigeret af
                    #710

                    Tillykke til Uttrup. Endnu en dansk etapesejr 🙂

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #711

                      JNJ recently repeated they expect peak sales over $5bn LLi, at 8-10% royalty. Further approval is key ofcourse, and i am not sure how far they could get there, but it could be bigger as Kesimpta

                      1 Reply Last reply
                      0
                      • K Offline
                        K Offline
                        kkjoel
                        wrote on sidst redigeret af
                        #712

                        EL, wasn't Amivantamab royalties "low double digit"? (translating to 10-12%, I imagine)

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #713

                          4/5 10:57
                          af E L
                          that is what i thought until i read in the last annual report "m. Under our agreement with Janssen, Genmab will receive milestones and royalties between 8% and 10% on net sales of RYBREVANT."

                          1 Reply Last reply
                          0
                          • D Offline
                            D Offline
                            deleted-user
                            wrote on sidst redigeret af
                            #714

                            Thx. So we got a NAV around 50 pts. and a max. at 250 pts

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #715

                              Ik think that is fair, what's 250dkk, roughly $2,2bn? On top of my head, in 10-15yrs it could make $30-35bn FV, discounted at a decent risk rate?
                              Further approvals should slowly unlock that

                              1 Reply Last reply
                              0
                              • D Offline
                                D Offline
                                deleted-user
                                wrote on sidst redigeret af
                                #716

                                That assumption seems sober. Its so easy to see the future via my beloved BA II plus 🙂

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #717

                                  Lol, you an old accountant or something? I grew up with an HP 28 haha, but as I am sitting next to the pool i have to use my own -small- brain 😉

                                  1 Reply Last reply
                                  0
                                  • D Offline
                                    D Offline
                                    deleted-user
                                    wrote on sidst redigeret af
                                    #718

                                    yeah a (young) old accountant with a degree in finance. Wow. An HP28 thats original. I guess that is just a bit more recent than the abacus Helge grew up with 😄 Enjoy the pool time. Over and out.

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #719

                                      that Hexelect article Peter posted earlier was reviewed by 2 Seagen employees https://www.nature.com/articles/s41587-022-01401-3 (behind a paywall)

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #720

                                        USA/lukning: Tunge aktiefald inden Fed-nyt og tech-regnskaber https://www.proinvestor.com/investornyt/855861/usa-lukning-tunge-aktiefald-inden-fed-nyt-og-tech-regnskaber

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #721

                                          Good old alemtuzumab targeted CD52 and made the same move as ofatumumab - from CLL to MS. But would be nice to see HexElect in action sooner than later

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper